RANKL Antibody for Acute Charcot Neuro-osteoarthropathy
Status:
Active, not recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This study's goal was to determine how denosumab 60 mg, combined with total contact casting
and restricted weightbearing status, would affect the treatment of acute CN with CKD.
METHODS Participants in the research were those who visited the outpatient foot clinic at
PGIMER, CHD in India. During the study period, 446 persons with CN were identified, 102 of
whom met the criteria for the first screening, and 60 of whom were ultimately enrolled in the
study.
Aim: To assess the clinico-radiological remission of Acute Charcot-neuroarthropathy in
patients of CKD.
Phase:
Phase 4
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research